The FDA-approved drugs for AML, beyond standard chemotherapy, include gemtuzumab ozogamicin [38], hypomethylating agents [39], FLT3 (Fms-like tyrosine kinase 3) inhibitors [40], IDH (isocitrate dehydrogenase) inhibitors [41], venetoclax [42], CPX-351 (liposomal cytarabine and daunorubicin), also called Vyxeos [43], and hedgehog pathway inhibitors [44]. This evidence concerns the gene IDH3A and acute myeloid leukemia.